. 2021 Mar 8;87(10):3643–3646. doi: 10.1111/bcp.14800

TABLE 1.

Pharmacological characteristics of different SGLT inhibitors

	Drug	SGLT2 over SGLT1 selectivity	Site of action	Glucose‐lowering action by	HbA1c reduction (%) ^a	Anti‐inflammatory potency	Effects on heart failure and kidney disease outcomes
SGLT2 inhibitors	Empagliflozin	2500‐fold	Almost exclusively kidney	Reducing renal glucose reabsorption	0.7–0.9	Similar	Beneficial
	Ertugliflozin	2000‐fold			0.5
	Dapagliflozin	1200‐fold			0.5–0.7
Dual inhibitors	Canagliflozin	250‐fold	Mostly in kidney and small intestine	Reducing renal glucose reabsorption and dietary absorption of glucose and galactose	0.91–1.16
Dual inhibitors	Sotagliflozin	20‐fold	Mostly in kidney and small intestine		0.52–0.92

Abbreviations: HbA1c, glycated haemoglobin; SGLT, sodium‐glucose co‐transporters.

^{^a}

Data refer to individual and not to head‐to‐head trials.